IBD Research The Ultimate Team Sport

Ann and Richard Frankel Chair in Pediatric IBD
Director of the Very Early-Onset IBD Program
Division of Gastroenterology, Hepatology and Nutrition
The Children's Hospital of Philadelphia





Life with IBD: The Old Days

- Steroids
- Surgery





Then came Remicade



Infliximab (Remicade) Therapy in The Treatment of Pediatric Crohn'S Disease

Baldassano, Robert, MD¹; Braegger, Christian P, MD²; Escher, Johanna C, MD³; DeWoody, Kimberly, PhD⁵; Hendricks, David F⁵; Keenan, Gregory F, MD⁵; Winter, Harland S, MD⁴

Journal of Pediatric Gastroenterology and Nutrition 33:S19-S26 © September 2001 Lippincott Williams & Wilkins, Inc., Philadelphia

Surpassing Conventional Therapies: The Role of Biologic Therapy

Robert N. Baldassano




Safety and Efficacy of Adalimumab for Moderate to Severe Crohn's Disease in Children


Vedolizumab Therapy in Severe Pediatric Inflammatory Bowel Disease

Máire A. Conrad, MD, MS,* Ronen E. Stein, MD,* Elizabeth C. Maxwell, MD, MS,* Lindsey Albenberg, DO,*,† Robert N. Baldassano, MD,*,† Noor Dawany, PhD,† Andrew B. Grossman, MD,*,† Petar Mamula, MD,*,† David A. Piccoli,*,† and Judith R. Kelsen, MD*,†









James D. Lewis,^{6,7,9} Eric Z. Chen,^{6,9} Robert N. Baldassano,¹ Anthony R. Otley,³ Anne M. Griffiths,⁴ Dale Lee,¹.² Kyle Bittinger,³ Aubrey Bailey,⁵ Elliot S. Friedman,² Christian Hoffmann,⁵ Lindsey Albenberg,¹ Rohini Sinha,⁵ Charlene Compher,⁵ Erin Gilroy,⁶ Lisa Nessel,⁶ Amy Grant,³ Christel Chehoud,⁶ Hongzhe Li,⁶ Gary D. Wu,^{7,∗} and Frederic D. Bushman^{6,∗}





Efficacy of Combination Antibiotic Therapy for Refractory Pediatric Inflammatory Bowel Disease

Jessica Breton, MD,*® Arthur Kastl, MD,* Natalie Hoffmann, MD,† Rachel Rogers, MS,‡ Andrew B. Grossman, MD,* Petar Mamula, MD,* Judith R. Kelsen, MD,* Robert N. Baldassano, MD,* and Lindsey Albenberg, DO*









Loci on 20q13 and 21q22 are associated with pediatric-onset inflammatory bowel disease

ORIGINAL ARTICLE

Targeted resequencing identifies defective variants of decoy receptor 3 in pediatric-onset inflammatory bowel disease

CJ Cardinale¹, Z Wei², S Panossian¹, F Wang¹, CE Kim¹, FD Mentch¹, RM Chiavacci¹, KE Kachelries³, R Pandey¹, SFA Grant^{1,4}, RN Baldassano^{3,4} and H Hakonarson^{1,4}

Very Early Onset Inflammatory Bowel Disease (VEO-IBD) Program

Common Threads in Pediatric Inflammatory Diseases Insight Into Personalized Medicine

Trusha T. Patel, MD; Maire A. Conrad, MD; Judith R. Kelsen, MD

Newly identified gene variants may contribute to development of very early onset IBD

Kelsen JR, et al. *Gastroenterology*. 2015;doi:10.1053/j.gastro.2015.07.006. September 8, 2015

Researchers have identified novel gene variants that regulate B- and T-cell functions in patients with very early onset inflammatory bowel disease, which may contribute to disease development.



PETAR MAMULA ANDREW B. GROSSMAN ROBERT N. BALDASSANO JUDITH R. KELSEN JONATHAN E. MARKOWITZ EDITORS

Pediatric Inflammatory Bowel Disease

Third Edition





How Were These Discoveries Made?

• You!

Patients and families are the key to curing this disease!

IBD Research Coordinators



Kelly Kachelries
Clinical Research Program Manager



Rawan Shraim



Audrey Merz



Kristen Plantz



Dylan Selden



Vivian Chang



Sarah Weinbrom



Sarah Neukrug



Nina Devas



Sarah Rowley



Sarah Dozil



Naomi Pressman



Shelly Zilber



How can you help?

https://www.chop.edu/pages/inflammatory-bowel-disease-

research



